Endocrine Neoplasm - Neuroendocrine Cancer
NCT00569127
Clinical Trial Information
Trial Number: NCT00569127 (ClinicalTrials.gov)
Disease Type:
- Endocrine Neoplasm - Neuroendocrine Cancer
Trial Title:
Phase III Prospective Randomized Comparison of Depot Octreotide Plus Interferon Alpha Versus Depot Octreotide Plus Bevacizumab (NSC #704865) in Advanced, Poor Prognosis Carcinoid Patients
Study ID:
S0518
Images are available?:
No
Is this a NCI-MATCH Trial?:
No
Datasets Linked to Trial
| Title | Description |
|---|---|
| NCT00569127-D2 | This dataset will allow users to reproduce toxicity analyses reported in the Journal of Clinical Oncology (Yao et al., JCO, 2017, PMID referenced above), which included adverse events among patients with advanced NETs in the SWOG Phase III trial, S0518 (NCT00569127), receiving bevacizumab + octreotide or interferon alfa-2b + octreotide. |
| NCT00569127-D1 | This dataset will allow users to reproduce efficacy analyses reported in the Journal of Clinical Oncology (Yao et al., JCO, 2017, PMID referenced above), which included results evaluating bevacizumab or interferon alfa-2b added to octreotide among patients with advanced NETs in the SWOG Phase III trial, S0518 (NCT00569127). |
Accessibility | Disclaimer | FOIA | HHS Vulnerability Disclosure | Privacy & Security
U.S. Department of Health and Human Services | National Institutes of Health | National Cancer Institute | USA.gov
NIH…Turning Discovery Into Health®